Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis

ar2478 ARJ Research article Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis Zhao Xiaoyan xyzhao@stanford.edu Okeke Lance Nwora lance.okeke@duke.edu Sharpe Orr osharpe@stanford.edu Batliwalla M Franak fb@nshs.edu Lee T Annette anlee@nshs.edu Ho P Peggy pegpho@stanford.edu Tomooka H Beren btomooka@gmail.com Gregersen K Peter peterg@nshs.edu Robinson H William wrobins@stanford.edu

GRECC, VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, USA

Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, 269 Campus Drive West, Stanford, CA 94305, USA

Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 269 Campus Drive West, Stanford, CA 94305, USA

Arthritis Research & Therapy 1478-6354 2008 10 4 R94 http://arthritis-research.com/content/10/4/R94 See related editorial by van Venrooij and Pruijn, http://arthritis-research.com/content/10/5/117 18710572 10.1186/ar2478 10 6 2008 01 7 2008 22 7 2008 18 8 2008 18 8 2008 2008 Zhao et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction

There is increasing evidence that autoantibodies and immune complexes (ICs) contribute to synovitis in rheumatoid arthritis (RA), yet the autoantigens incorporated in ICs in RA remain incompletely characterised.

Methods

We used the C1q protein to capture ICs from plasma derived from human RA and control patients. Antibodies specific for immunoglobulin were used to detect ICs, and fibrinogen antibodies were used to detect fibrinogen-containing ICs. RA and control plasma were separated by liquid chromatography, and fractions then characterised by ELISA, immunoblotting and mass spectrometry. Immunohistochemical staining was performed on rheumatoid synovial tissue.

Results

C1q-immunoassays demonstrated increased levels of IgG (p = 0.01) and IgM (p = 0.0002) ICs in plasma derived from RA patients possessing anti-cyclic citrullinated peptide (CCP+) autoantibodies as compared with healthy controls. About one-half of the anti-CCP+ RA possessed circulating ICs containing fibrinogen (p = 0.0004). Fractionation of whole RA plasma revealed citrullinated fibrinogen in the high molecular weight fractions that contained ICs. Positive correlations were observed between fibrinogen-containing ICs and anti-citrullinated fibrinogen autoantibodies, anti-CCP antibody, rheumatoid factor and certain clinical characteristics. Immunohistochemical staining demonstrated co-localisation of fibrinogen, immunoglobulin and complement component C3 in RA pannus tissue. Mass spectrometry analysis of immune complexes immunoprecipitated from RA pannus tissue lysates demonstrated the presence of citrullinated fibrinogen.

Conclusion

Circulating ICs containing citrullinated fibrinogen are present in one-half of anti-CCP+ RA patients, and these ICs co-localise with C3 in the rheumatoid synovium suggesting that they contribute to synovitis in a subset of RA patients.

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune synovitis affecting 0.6% of the world's population 1, yet the mechanisms underlying the initiation and progression of RA are still not completely understood. The presence of immune complexes (ICs) in the blood and synovial fluid of patients with RA is well described 23, and there is evidence they are involved in the activation of the complement cascade in RA synovial tissue 4. However, apart from rheumatoid factor (RF) 5 and anti-collagen type II 6, the identity of the antigens involved in ICs in RA remains obscure.

Studies suggest critical roles for protein citrullination, B cells and autoantibodies in the pathogenesis of RA 78910. Citrullination is the post-translational conversion of arginine to citrulline, and in RA autoantibodies targeting cyclic citrullinated peptide (CCP) provides a sensitivity of approximately 70% and a specificity of 97% for the diagnosis of RA 71112. The citrullinated α- and β-chains of fibrin have been identified as potential targets of the autoantibody response in RA 13 and citrullinated fibrinogen is detected in RA synovial fluid 14.

Korganow and colleagues identified ICs involving glucose-6-phosphate isomerase (GPI) as mediating joint inflammation in their spontaneous K/BxN model 15. These mice produce anti-GPI antibodies that form ICs that are deposited on articular surfaces and activate the alternative complement pathway to cause synovitis. Although studies suggest that GPI is not a specific autoantigen in RA 16, it is possible that the mechanisms involved in anti-GPI antibody arthritis and IC arthritis are relevant to a subset of human RA patients.

RA is characterised by excessive generation and breakdown of fibrinogen 17. The citrullinated α- and β-chains of fibrin have also been identified as a potential target of the autoantibody response in RA 1318 and citrullinated fibrinogen has been identified in synovial fluid derived from RA patients 14. Autoantibodies against citrullinated fibrinogen have been described to provide diagnostic value in arthritis 1819. We previously generated synovial microarrays containing more than 500 proteins and peptides representing candidate autoantigens in RA, including protein and overlapping peptides representing native and citrullinated fibrinogen. Synovial microarray analysis demonstrated targeting of citrullinated fibrinogen in RA 20.

The methods described for the detection of ICs include chemical precipitation methods from as far back as the 1960s 21 and biological methods such as precipitation with Clq 22. We adapted C1q capture immunoassays to utilise fibrinogen-specific secondary antibodies to identify fibrinogen-containing ICs, and applied these immunoassays to plasma samples derived from RA and control patients.

In the present study, we further investigated the targets of the autoantibody response and the antigens incorporated in ICs in RA. We demonstrated that one-half of anti-CCP+ RA patients possessed circulating (blood) ICs containing citrullinated fibrinogen, and that fibrinogen, immunoglobulin and complement component C3 co-localize in pannus tissue derived from RA patients. These data suggest that autoantibody targeting of citrullinated fibrinogen results in the formation of fibrinogen-containing ICs that characterise a subset of anti-CCP+ RA patients and may contribute to synovitis in RA.

Materials and methods

Human samples

All RA and control plasma and joint samples were obtained and studied with informed consent under Institutional Review Board approved protocols. The plasma samples used came from the Multiple Autoimmune Disease Genetics Consortium 23 and the Stanford Arthritis Center, collected in EDTA tubes (Table 1). The diagnosis of RA was made based on the American College of Rheumatology 1987 criteria 24.

Table 1

Source and description of samples used in the study

Sample source

Disease

Number

Female, no. (%)

Age (range)

anti-CCP positive, no. (%)

RF positive, no. (%)

Dr. P. Gregersen, plasma set 1

28 (93)

72.6 (51 to 89)

20 (67)

24 (80)

Healthy

Dr. P. Gregersen, plasma set 2

IBD

13 (65)

46.4 (23 to 82)

JRA

16 (80)

37.3 (10 to 71)

6 (30)

PsA

11 (79)

52.6 (23 to 75)

10(50)

55.3(22 to 86)

19(95)

59.0(35 to 89)

SLE

13 (65)

51.3 (29 to 67)

CCP, cyclic-citrullinated peptides; RF, rheumatoid factor; RA, rheumatoid arthritis; IBD, inflammatory bowel disease; JRA, juvenile rheumatoid arthritis; PsA, psoriatic arthritis; PS, psoriasis; SLE, systemic lupus erythematosus.

Mass spectrometry analysis

For in-gel digestion, protein spots were excised from the gel and treated with trypsin overnight at 37°C. The tryptic peptides were resolved by high-performance liquid chromatography (HPLC) using a Zorbax 300SB-C18 nanocolumn (Agilent Technologies, Palo Alto, CA, USA) packed with 3.5 μm particles (Agilent Technologies, Palo Alto, CA, USA) and eluted at 300 nL/minute with a 60 minute linear gradient from 0 to 95% acetonitrile containing 0.1% formic acid. Separated peptides were electrosprayed into an ion trap mass spectrometer (XCT Plus, Agilent Technologies, Palo Alto, CA, USA). For ICs immunoprecipitated from RA pannus tissue lysates, the precipitated complexes were directly digested with trypsin before mass spectrometry analysis. Proteins were identified based on raw MS/MS data compared with a SwissProt database using Mascot (Matrix Science, UK) with valid peptide hits.

Detection of anti-citrullinated fibrinogen autoantibodies

Native fibrinogen (Calbiochem, San Diego, CA, USA) was citrullinated in vitro with a peptidylarginine deiminase derived from rabbit skeletal muscle (Sigma, St. Louis, MO, USA) using protocols previously described 25. Anti-citrullinated fibrinogen autoantibodies were assayed as previously described 132627. Briefly, native fibrinogen or citrullinated fibrinogen was coated on ELISA plates (MaxiSorp; Nunc, Rochester, NY, USA) overnight at 4°C at a concentration of 20 μg/mL. Subsequent incubations and washes were performed at room temperature. The plates were blocked with 3% bovine serum albumin (BSA) in phosphate buffered saline with 0.05% Tween-20 (PBST) (Sigma, St. Louis, MO, USA) for one hour, washed and incubated with centrifuged plasma (diluted 50-fold) on a shaker for 1.5 hours. Anti-fibrinogen autoantibody was detected using horseradish peroxidase (HRP)-conjugated secondary reagents specific for human IgG (γchain) or IgM (μchain) specific antibodies diluted to 1:20,000.

Quantitation of immune complexes

ELISA plates were coated with 20 μg/mL C1q (Sigma, St. Louis, MO, USA) in phosphate buffered saline (PBS) overnight at 4°C. Subsequent incubations and washes were performed at room temperature. The plates were blocked with 3% BSA in PBST for one hour. After washing, plasma from RA patients or healthy controls were diluted to 1:50 in PBST and incubated on a shaker for 1.5 hours. ICs were detected with HRP-conjugated rabbit antiserum specific for human IgG or IgM (Jackson Immunoresearch, West Grove, PA, USA).

Quantitation of fibrinogen-containing immune complexes

ELISA plates coated with C1q were blocked with 3% BSA in PBST for one hour. After washing, plasma from RA patients or healthy controls was diluted to 1:10 and incubated on a shaker for 1.5 hours. Fibrinogen contained within the captured ICs was detected using a 1:4000 dilution of HRP-conjugated rabbit anti-human fibrinogen antiserum (Dako, Carpinteria, CA, USA).

Anti-CCP and RF (IgM) ELISA

The anti-CCP (Euro Diagnostica, Malmö, Sweden) and RF ELISA kits (Alpha Diagnostic International, San Antonio, TX, USA) were used according to the manufacturers' protocol, except that plasma was used instead of serum. Anti-CCP and RF values of the samples were expressed as IU/mL.

Fractionation of plasma samples

The plasma samples were filtered by a 0.45 μm cellulose acetate membrane in a Spin-x centrifuge tube filter (Corning, Corning, NY, USA) to remove cell debris and precipitates. A volume of 150 μL of the filtered plasma sample was injected into a fast protein liquid chromatography (FPLC) system (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) equipped with a Superdex 200 10/300 gel filtration column (Amersham Biosciences, Piscataway, NJ, USA). A mixture of protein standard containing human fibrinogen, human albumin and IgG was run in parallel to further identify different peaks. All liquid chromatography runs were programmed at a flow rate of 0.4 mL/minute with PBS and fractions of 0.5 mL were collected. To measure total protein content of the fractions, 20 μL of each fraction was mixed with 100 μL of BCA buffer (Pierce Biotechnology, Rockford, IL, USA) and the mixture was incubated at 37°C for 30 minutes before the results were read at 562 nm on a spectraMAX190 instrument (Molecular Devices, Sunnyvale, CA, USA). To measure IgG and fibrinogen ICs, 50 μL of each fraction was applied to the C1q ELISA described above. To measure total IgG and fibrinogen content, the fractions were first diluted 10-fold with PBS. Then 1 μL of the dilutes was deposited onto a nitrocellulose membrane and left to dry overnight. After blocking with 5% milk in PBST, HRP-conjugated anti-human IgG or anti-human fibrinogen was applied to the membranes. Detection was carried out with SuperSignal West Pico Substrate (Pierce Biotechnology, Rockford, IL, USA). The densitometry of exposed film were measured with FluorChem imaging system (Alpha Innotech, San Leandro, CA, USA).

Immunoblot

Plasma fractions were further separated with Precast Criterion Tris-HCl gels (4 to 20% linear gradient; Bio-Rad, Hercules, CA, USA), and separated proteins blotted onto nitrocellulose membranes. After blocking with 3% BSA in PBS, sera from RA patients or healthy controls were used to probe the membranes. Bound antibodies were detected with HRP-conjugated anti-human IgG (Jackson Immunoresearch, West Grove, PA, USA) using a SuperSignal kit (Pierce biotechnology, Rockford, IL, USA) and chemiluminescence was imaged with FluorChem imaging system (Alpha Innotech, San Leandro, CA, USA). Immunoblot with anti-modified citrulline was performed with an anti-citrulline detection kit (Upstate, Chicago, IL, USA) according to the manufacturer's instructions 1327.

Immunohistochemistry

Slides were deparaffinised and hydrated with water. Endogenous peroxidase was inhibited with 3% hydrogen peroxide, and non-specific staining blocked with DAKO Protein Block Serum-Free (Dako, Carpinteria, CA, USA). Staining for complement C3 was performed using a 1:2000 dilution of rabbit polyclonal antibodies against human complement C3 (Dako, Carpinteria, CA, USA). For fibrinogen and IgG staining, pretreatment of proteinase K (Dako, Carpinteria, CA, USA) was used before the primary antibody incubation. Slides positive for fibrinogen were immunohistochemically stained with a rabbit polyclonal antibody against human fibrinogen (Dako, Carpinteria, CA, USA), at room temperature at a dilution of 1:1600 for 30 minutes. After incubation with primary antibody, the tissue sections were sequentially incubated with Dako Envision+ Rabbit System Labeled Polymer HRP (Dako, Carpinteria, CA, USA) or biotinylated rabbit anti-goat antibodies (Vector, Burlingame, CA, USA) followed by streptavidin HRP (Dako, Carpinteria, CA, USA). Staining was developed with Liquid DAB+ (Dako, Carpinteria, CA, USA) and counterstained with haematoxylin and eosin.

Statistics

All statistics were run using InStat™ software (GraphPad Software Inc., San Diego, CA, USA). For quantitation of ICs and autoantibodies to fibrinogen, unpaired t-tests with Welch correction were used.

Results

Identification of fibrinogen-containing circulating immunecomplexes in RA

C1q binds aggregated immunoglobulin Fc regions and has been used to capture and quantitate ICs 28. We used C1q-capture immunoassays and HRP-labelled secondary antibodies specific for human IgG and IgM to quantitate circulating ICs in plasma derived from anti-CCP+ RA, anti-CCP- RA and healthy control patients (Figures 1a,b). Elevated circulating IgG (p = 0.01; Figure 1a) and IgM (p = 0.0002; Figure 1b) ICs were observed in anti-CCP+ RA patients when compared with healthy controls. Most anti-CCP- RA patients did not possess circulating ICs (Figures 1a,b).

Figure 1

Fibrinogen-containing circulating immune complexes (ICs) in rheumatoid arthritis (RA)

Fibrinogen-containing circulating immune complexes (ICs) in rheumatoid arthritis (RA). Circulating (a) IgG and (b) IgM ICs were detected in plasma derived from healthy individuals and anti-cyclic-citrullinated peptides (CCP) – and anti-CCP+ RA patients. ELISA plates were coated with C1q, incubated with 1:50 dilutions of plasma samples and horseradish peroxidase (HRP)-conjugated (a) anti-IgG or (b) anti-IgM secondary antibodies were used to detect the immunoglobulin isotypes contained in ICs. (c, d) Circulating fibrinogen-containing ICs were detected using HRP-conjugated fibrinogen-specific antisera as the secondary reagent. Statistical comparisons are based on an unpaired t-test with Welch correction. (e) Fibrinogen-containing ICs were detected with different dilutions of RA patient samples and healthy controls. Error bars represent the standard deviation of results from triplicate wells. (f) Fibrinogen-containing ICs were detected in fresh plasma and freeze-thawed plasma samples with no significant differences in values (data for anti-CCP status of RA5 is not available).

To determine if circulating ICs containing fibrinogen are present in RA, a fibrinogen-specific secondary antibody was used after C1q capture. One-half of anti-CCP+ RA patients possessed fibrinogen-containing ICs when compared with healthy controls (p = 0.0004) and anti-CCP- RA patients (p = 0.0008) (Figure 1c). Anti-CCP+ RA patients showed elevated titres of fibrinogen-containing ICs relative to anti-CCP- RA and healthy controls with low standard deviations (Figure 1e).

To further demonstrate that the observed fibrinogen-containing ICs did not result from non-specific binding of fibrinogen to immobilised C1q, we immobilised anti-C1q monoclonal antibodies to capture the C1q-bound ICs followed by detection with anti-fibrinogen antibodies. Similar results were obtained with anti-C1q monoclonal antibody capture as compared with C1q capture of ICs, and yielded a R²value of 0.9 in a linear regression analysis of the two assays (data not shown). Fibrinogen-containing ICs were also analysed from freshly collected plasma samples from both anti-CCP+ RA and anti-CCP- RA patients (within two hours of blood draw using EDTA plasma collection tubes). Compared with the same samples after a freeze-thaw cycle, no difference was detected (Figure 1f).

To demonstrate that fibrinogen-containing ICs were specifically detected in RA compared with other autoimmune diseases, these ICs were analysed from plasma samples collected in a panel of healthy (n = 10), inflammatory bowel disease (n = 20), juvenile RA (n = 20), psoriatic arthritis ([PsA] n = 14), psoriasis (n = 20), systemic lupus erythematosus (n = 20), and RA (n = 20) patients (Figure 1d). A subset of RA and a small subset of juvenile RA patients exhibited elevated circulating ICs containing fibrinogen, while patients with other autoimmune diseases did not (Figure 1d). The subset of juvenile RA patients possessing circulating ICs containing fibrinogen also possessed anti-citrullinated fibrinogen antibodies, RF and anti-CCP antibodies (Table 2). Chart reviews performed on this subset of juvenile RA patients revealed that they exhibited symmetrical polyarthritis (Table 2). These observations suggest that this subset of 'juvenile RA' patients in fact have adult RA, and is consistent with prior reports of 13% of juvenile RA patients exhibiting anti-CCP antibodies and clinical features consistent with adult RA 29.

Table 2

Clinical and laboratory characteristics of the juvenile rheumatoid arthritis (JRA) patients characterised

Sample

Clinical features and rheumatoid factor status

Age

Onset

Age

History

Fibrinogen ICs (O.D.)

Anti-cit. fibrinogen IgG (O.D.)

anti-CCP^a

(IU/mL)

RF^b

(IU/mL)

JRA 1

Polyarthritis, RF-

0.18

0.11

21.3

11.7

JRA 4

Polyarthritis, RF+

0.77

1.25

841.1

127.6

JRA 8

Polyarthritis, RF+

0.53

0.43

483.2

262.6

JRA 13

Polyarthritis, RF+

0.54

1.45

255.4

274.7

JRA 17

Systemic arthritis

0.15

0.10

24.8

24.9

JRA 22

Polyarthritis, RF-

0.13

0.09

22.7

27.1

JRA 27

Polyarthritis, RF-

0.10

0.08

20.3

7.6

JRA 31

Persistent oligoarthritis

0.16

0.13

21.5

7.3

JRA 32

Polyarthritis, RF-

0.12

0.37

26.7

6.3

JRA 41

Enthesitis-related arthritis

0.14

0.08

20.8

13.1

JRA 42

Systemic arthritis

0.17

0.08

21.8

7.1

JRA 44

Polyarthritis, RF-

0.19

0.09

20.9

10.1

JRA 49

Polyarthritis, RF+

1.72

0.74

1275.4

295.2

JRA 51

Systemic arthritis

0.14

0.09

21.4

7.6

JRA 71

Polyarthritis, RF+

0.19

0.21

360.9

186.1

JRA 79

Polyarthritis, RF-

0.20

0.10

22.1

11.7

JRA 88

Polyarthritis, RF+

0.51

0.35

287.0

236.4

JRA 106

Extended oligoarthrits

0.15

0.12

22.0

10.0

JRA 110

Persistent oligoarthritis

0.15

0.10

24.9

14.6

JRA 112

Enthesitis related arthritis

0.14

0.12

22.5

15.9

^a,bMeasured with commercial kits. JRA, juvenile rheumatoid arthritis; IC, immune complex; CCP, cyclic-citrullinated peptides; RF, rheumatoid factor; O.D., optical density

Liquid chromatographic separation demonstrates co-fractionation of citrullinated fibrinogen with immune complexes

To demonstrate that the fibrinogen-containing ICs in plasma are physically distinct from free fibrinogen and free immunoglobulin, we used size exclusion chromatography as previously described 16. Size exclusion chromatography was applied to fractionate plasma derived from an RA patient with fibrinogen-containing circulating ICs, an RA patient with circulating ICs but not fibrinogen-containing circulating ICs, a PsA patient and a healthy control (Figure 2a). Forty-five fractions were generated of each patient's plasma and each fraction was assayed for ICs, fibrinogen-containing ICs, total immunoglobulin, total fibrinogen and total protein.

Figure 2

Citrullinated fibrinogen-containing immune complexes (ICs) are separated from rheumatoid arthritis (RA) plasma

Citrullinated fibrinogen-containing immune complexes (ICs) are separated from rheumatoid arthritis (RA) plasma. (a) Liquid chromatographic separation of RA plasma. Fast protein liquid chromatography (FPLC) was used to fractionate plasma derived from RA and control patients. Forty-five fractions were collected from each plasma sample, and individual fractions were analysed for total protein, fibrinogen, IgG, IgG ICs and fibrinogen ICs (FIC), and relative levels of each of these components are plotted. Plasma samples from two RA patients (RA1 and RA2), a psoriatic arthritis (PsA) patients and a healthy control were characterised. The right panel presents individual traces from patient RA1, with the dashed lines indicating the fractions containing the peak levels of ICs, free fibrinogen and free Ig. (b) Citrullinated fibrinogen was identified by anti-modified citrulline blot. (c) In-gel trypsin digestion of the bands followed by mass spectrometry revealed two citrullinated peptides derived from beta chain of human fibrinogen.

ELISA analysis of the fractions containing IgG ICs showed two peaks in the elution profile of both RA samples, but not in the corresponding fractions from the PsA and healthy control samples (Figure 2a, green line). The first peak (RA1 and RA2, green line) corresponded to the first three fractions after the void volume, which had a molecular mass of 300 kD or higher, and corresponded to the fractions in which ICs eluted. The second peak (RA1 and RA2, green line) corresponded to free IgG as compared with a chromatography run of standards (STD, blue line). ELISA analysis of fibrinogen ICs on RA1 (which possessed fibrinogen ICs) showed a single peak (Figure 2a, RA1, red line) that was eluted in the same fractions at the IgG IC peak (Figure 2a, RA1 and RA2, first peak of green line). Similar analysis on RA2 did not show a co-eluted peak (RA2, red line).

To further determine that fibrinogen detected from IC fractions was not a contamination from free fibrinogen in blood, free fibrinogen from each RA1 fraction was quantitated by dot assay (Figure 2a, right panel, pink line). The peak of free fibrinogen was well separated from the peak of fibrinogen IC (Figure 2a, right panel, red line), as shown by the first two dotted lines. PsA and healthy control patients did not possess circulating ICs (PsA and healthy, green line). It is possible that following the collection of the plasma fractions, that the free IgG fractions that contained high levels of IgG developed some IgG aggregates that were then detected by the IgG IC assay. These results demonstrate that the fibrinogen-containing circulating ICs observed co-elute with the IgG ICs, and that the fractions containing fibrinogen-ICs are distinct from those containing free fibrinogen and free immunoglobulin.

To determine if the fibrinogen present in circulating ICs is citrullinated, the FPLC fractions that contained fibrinogen ICs were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with anti-modified citrulline antibody (Figure 2b). Citrullinated polypeptides that co-migrated with fibrinogen polypeptides were detected only in the fractions derived from RA patients but not in the corresponding fractions isolated from controls. The band, indicated as fibrinogen beta chain, was further analysed by mass spectrometry. Two distinct citrullinated peptides from the fibrinogen beta chain were identified (Figure 2c).

Laboratory and clinical features associated with fibrinogen-containing circulating immune complexes

We observed positive correlations between fibrinogen-containing ICs with IgG and IgM ICs, anti-citrullinated fibrinogen antibodies, anti-CCP antibodies, RF and certain clinical characteristics (Figures 3a–h). Of anti-CCP+ RA patients, three-quarters possess anti-citrullinated fibrinogen antibodies (Figures 3c, i) and one-half possess fibrinogen-containing circulating ICs (Figures 3d, i). All patients with fibrinogen-containing circulating ICs possess RF, while more than one-half of RF+ patients did not possess fibrinogen-containing ICs (Figures 3e, i). Interestingly, fibrinogen-containing ICs were not detected in a subset of the RA patients who possessed high IgG and IgM plasma ICs, suggesting that circulating ICs containing other antigens are present in this subset of RA patients (Figures 3a,b). In RA patients, the presence of circulating ICs containing fibrinogen was associated with a disease duration of more than 10 years (p = 0.02; Figure 3g), and there were trends towards associations with smoking (p = 0.1; Figure 3h).

Figure 3

Fibrinogen-containing circulating immune complexes (ICs) are associated with anti-cyclic-citrullinated peptides (CCP) antibodies, rheumatoid factor (RF) and a disease duration of more than 10 years

Fibrinogen-containing circulating immune complexes (ICs) are associated with anti-cyclic-citrullinated peptides (CCP) antibodies, rheumatoid factor (RF) and a disease duration of more than 10 years. Scatter plots are presented for the association of (a, b) fibrinogen ICs with IgG and IgM ICs; (c) anti-citrullinated fibrinogen antibodies with anti-CCP antibodies; (d) fibrinogen ICs with anti-CCP antibodies; (e) RF; and (f) anti-citrullinated fibrinogen. Lines were drawn to mark the negative and positive measurements of each species. (g, h) Levels of fibrinogen ICs are also plotted in RA patients with (g) more than 10 years disease duration and (h) smoking history. (i) Unsupervised hierarctical clustering 54 of 30 RA patients and levels of fibrinogen-circulating ICs, anti-citrullinated fibrinogen antibodies, RF and anti-CCP are presented as a heatmap. Tree dendrograms represent the statistical relatedness between patients.

Unsupervised hierarchical clustering of 30 RA patients based on their anti-CCP antibody, RF, anti-citrullinated fibrinogen antibody and fibrinogen-containing circulating IC levels demonstrates statistical groupings (Figure 3i). The anti-CCP+ RF+ patients cluster together, and more than one-half of these patients possess anti-citrullinated fibrinogen autoantibodies and circulating ICs containing fibrinogen.

Immunohistochemistry demonstrates co-staining of fibrinogen, complement component C3, and immunoglobulin in pannus tissue derived from RA patients

To further investigate the role of fibrinogen-containing ICs in RA, we performed immunohistochemistry on remnant pannus tissue derived from two anti-CCP+ RF+ RA patients. Pannus tissue was obtained from RA patients at the time of knee arthroplasty, fixed and sectioned, then consecutive sections were stained with antibodies specific for complement component C3, fibrinogen and immunoglobulin. Representative results are presented from the analysis of consecutive sections of pannus derived from two independent patients. Immunohistochemical staining demonstrates co-localisation of the complement component C3, fibrinogen, and IgG in both RA patients (Figures 4a,b).

Figure 4

Synovial tissue immune complexes (ICs) contain citrullinated fibrinogen

Synovial tissue immune complexes (ICs) contain citrullinated fibrinogen. (a, b) immunohistochemistry demonstrates co-localisation of fibrinogen, complement component C3 and immunoglobulins in rheumatoid arthritis (RA) pannus tissue. Representative staining of synovium derived from two separate cyclic-citrullinated peptides (CCP) + rheumatoid factor (RF) + RA patients are shown in (a) and (b). Immunohistochemistry was performed on articular cartilage samples derived from RA patients. Samples were fixed, paraffin-embedded and sections stained with antisera specific for complement component C3, fibrinogen and IgG, as well as with matched pre-immune sera. Horseradish peroxidase (HRP)-conjugated secondary antibodies were utilised to detect primary antibody reactivity. These stainings demonstrate co-localisation of complement component C3, fibrinogen and immunoglobulin staining at the surface of the articular cartilage sections. (c) Mass spectrometry analysis of ICs immunoprecipitated from RA synovial tissue demonstrates the presence of citrullinated fibrinogen peptides.

RA synovial tissue was minced and the protein contents extracted with tissue protein extraction buffer. Lysates were immunoprecipitated with protein-G-sepharose to capture ICs present in the rheumatoid synovial tissue. These ICs were eluted from the protein-G beads, trypsinised and the trypsin digests directly analysed by mass spectroscopy to demonstrate the presence of citrullinated fibrinogen in ICs isolated from RA pannus tissue (Figure 4c). These data suggest that citrullinated-fibrinogen containing ICs either deposit or form in synovial tissue in RA. The co-localisation of citrullinated fibrinogen-containing ICs with complement component C3 in RA pannus further suggests that they could activate the complement cascade to cause synovitis in RA.

Discussion

The presence of ICs in the blood and inflamed joints of patients with RA was described decades ago 30, and several recent findings have resulted in a resurgence of interest in the role of autoantibodies and B cells in RA. These findings include the facts that: anti-citrullinated protein autoantibodies can predate the development of clinical arthritis and provide a sensitivity of approximately 70% and a specificity of 97% for the diagnosis of RA 7111231; anti-CD20-mediated B cell depletion provides efficacy in treating RA 9; and the K/BxN mouse model develops spontaneous arthritis mediated by antibodies targeting the ubiquitous glycolytic enzyme GPI 32. Although ICs have been isolated from RA patient plasma by means of polyethylene glycol precipitation 33 and C1q affinity columns 22, the identity of the antigens incorporated in these ICs is not well defined. In the present study we characterise circulating and synovial tissue ICs, and demonstrate the presence of circulating ICs containing fibrinogen in one-half of anti-CCP+ RA patients (Figure 1). We used immunoblotting and mass spectroscopy to demonstrate that the fibrinogen contained in these circulating ICs is citrullinated (Figures 2b,c), and that ICs isolated from RA pannus tissue also contain citrullinated fibrinogen (Figure 4c). Finally, we demonstrate co-localisation of complement component C3, fibrinogen and immunoglobulin in RA pannus tissue (Figures 4a,b), suggesting that these complexes contribute to synovitis in RA.

Although it is difficult to completely exclude the possibility that the ICs detected are formed in vivo rather than ex vivo, Figure 1f provides reassurance that freezing and freeze-thaw are not responsible for the observed ICs. Further, fibrinogen-containing ICs were not observed in plasma derived from patients with a variety of other inflammatory arthritidies for which the plasma was collected and stored alongside the anti-CCP+ RA plasma in which fibrinogen ICs were demonstrated (Figures 1c,d). Although complement containing ICs usually bind to erythrocytes and are transported to the liver for clearance, in plasma derived from anti-CCP+ RA patients we found circulating C1q-bound ICs that contain fibrinogen. Further, fibrinogen ICs were also detected by anti-C1q monoclonal antibody capture and results were concordant with our results from C1q capture of ICs (comparison of results yielded a R²value of 0.9 in linear regression; data not shown).

There is growing evidence that fibrin could be an important autoantigen in RA 1318. Consistent with previous findings 34, autoantibody reactivity is only observed against citrullinated fibrinogen, and not against its native form (data not shown). Although the anti-citrullinated fibrinogen antibodies observed in RA do not result in overt clinical haematological manifestations, RA is characterised by extravascular coagulation and the accumulation of fibrin in the arthritic joint 1735. It has been hypothesised that a local imbalance between coagulation and fibrinolysis contributes to pathogenesis, and it is possible that autoantibodies targeting citrullinated fibrinogen could contribute to this imbalance by altering the structural and/or functional properties of fibrinogen and/or fibrin.

Fibrin is one of the classical citrulline-modified proteins 36, and the presence of citrullinated fibrinogen and/or fibrin has been demonstrated in the rheumatoid joint 1437. Nevertheless, citrullinated fibrinogen is generated in inflamed synovia arising from a variety of inflammatory conditions 37. Our observation that ICs containing citrullinated fibrinogen are present in the plasma of anti-CCP+ RA patients, but not in plasma derived from anti-CCP- RA, anti-CCP-juvenile RA and PsA patients (Figures 1 and 2), suggests a potential role for citrullinated fibrinogen-containing circulating ICs in RA. Our mass spectrometry analysis of the fibrinogen contained in circulating ICs derived from anti-CCP+ RA patients demonstrated a few citrullinated peptides from the α-chain of fibrinogen, but these peptides were not included in Figure 2c because of low Mascot scores. Our results are consistent with several previous publications that describe citrullinated epitopes derived from the beta, but not the alpha, chain of fibrinogen 3839. Although trypsin has been described to be incapable of cleaving C-terminal to citrulline residues 40, two of the three citrullinated peptides identified contain a citrulline at the C-terminus (Figures 2c and 4c). Using mass spectrometry analysis, we have detected multiple citrullinated peptides with C-terminal citrullines (as well as non-C terminal citrullines) in tryspin digests of multiple different citrullinated proteins in several experiments. In addition, citrullinated peptides with C-terminal citrullines were also observed from multiple citrullinated proteins that were sent to and analysed by an independent mass spectrometry core facility. The explanation for this observation remains unclear, and it is possible that our results are due to altered trypsin cleavage, which is polypeptide sequence and/or trypsin reaction condition dependent. The highly significant Mascot scores of our reported citrullinated peptides (Figures 2c and 4c) support the validity of our results.

The excessive formation of fibrin in the rheumatoid joint in combination with its citrullination and structural properties that include repetitive antigenic motifs, could result in activation of B cells specific for citrullinated fibrinogen via cross-linking of surface immunoglobulin receptors. Citrullination of collagen was demonstrated to increase its immunogenicity and arthritogenicity in a rat arthritis model 41. Recently, immunisation with citrullinated fibrinogen was described to induce arthritis in human leucocyte antigen (HLA) DR4-IE expressing transgenic mice, demonstrating the arthritogenic potential of citrullinated fibrinogen in mice expression RA-associated major histocompatibility complex (MHC) class II molecules 42.

Fibrin and/or fibrinogen plays an important role in a variety of inflammatory and immunological processes. Multiple cells, including neutrophils and macrophages, express integrins and other receptors that bind fibrin and/or fibrinogen 43. Fibrinogen has also been hypothesised to serve as a structural scaffold for the formation and growth of pannus 44. Fibrinogen is chemotactic for endothelial cells that are involved in angiogenesis 45, which is integral to the formation of pannus. Fibrin deposits in RA synovial tissue are hypothesised to activate synovial fibroblast proliferation and cytokine release, as well as other inflammatory cell responses 17. Fibrinogen has been shown to stimulate macrophage chemokine secretion through TLR-4 46. Further, it was recently demonstrated that RA-specific autoantibodies complexed to citrullinated fibrinogen stimulate macrophages to produce TNF via engagement of FcγRIIa 47.

Cantaert and colleagues suggested that the expression of citrullinated proteins is essential but not sufficient for the development of RA, and that generation of well-defined citrullinated epitopes is likely to play a critical role 48. In this context, our results might suggest that the development of autoantibodies targeting citrullinated epitopes specific to fibrinogen might play an important role in the pathogenesis of RA. In further support of a potential pathogenic role for citrullinated fibrinogen in RA, it was recently demonstrated that citrullinated fibrinogen bound by autoantibodies present in RA patient sera stimulate macrophage through FcγRIIa to secrete TNF 47.

It was unexpected to observe autoantibodies targeting citrullinated fibrinogen along with fibrinogen-containing circulating ICs in a subset of juvenile RA patients (Figure 1 and Table 2). However, late-onset polyarticular juvenile RA is associated with RF-positivity in about 5% of patients, and has been considered to be identical to adult RA. Further, a recent report described 13% of polyarticular-onset juvenile RA patients exhibiting anti-CCP antibodies 29. Following the observation of anti-citrullinated fibrinogen autoatibodies and fibrinogen-containing circulating ICs in a subset of juvenileRA patients (Table 2), we performed chart reviews with anti-CCP and RF ELISA tests on these plasma samples. Of the six juvenile RA patients exhibiting elevated levels of anti-citrullinated fibrinogen antibodies, all exhibited a symmetrical polyarthritis and possessed RF antibodies. All but one of the six anti-CCP+ and RF+ juvenile RA patients possessed high levels of fibrinogen ICs. The age of disease onset of the anti-CCP+ and RF+ juvenile RA patients were 13, 11, 3, 13 and 9 years, and these patients were relatively older than the other juvenile RA patients included in this cohort. Interestingly, five out of six anti-CCP+ and RF+ juvenile RA patients possessed fibrinogen-containing ICs, compared with only 50% of anti-CCP+ and RF+ adult RA patients. This observation suggests that anti-fibrinogen autoimmunity and fibrinogen-containing ICs play a significant role in this subset of juvenile RA patients. Characterisation of larger cohorts of juvenile RA patients will be necessary to validate and further investigate this observation.

Immunohistochemical analysis demonstrated co-localisation of the staining for fibrinogen, complement component C3 and immunoglobulin in serial sections derived from RA pannus tissue (Figure 4). These results suggest that fibrinogen-containing ICs deposit on or form in synovial lining tissue, and activate the complement cascade to cause inflammatory arthritis. In the K/BxN model, arthritis is mediated by anti-GPI antibodies and was demonstrated to depend on FcRγ and components of the alternative complement pathway 49. It has been speculated that accumulation of ICs involving GPI may activate the alternative complement pathway to cause inflammatory arthritis 16. We hypothesise that autoantibodies targeting citrullinated fibrinogen could result in IC-mediated arthritis based on mechanisms analogous to those observed in the K/BxN model 16 and via macrophage FcγRIIa-mediated TNF production 47.

Anti-citrullinated fibrinogen autoantibodies were detected in three-quarters of anti-CCP+ RA patients (data not shown) while fibrinogen containing ICs were found in one-half (Figures 1 and 3). These observations are consistent with RA being a clinically and molecularly heterogeneous disease, as evidenced by differential expression of anti-citrulline antibodies 711, variable responsiveness to anti-tumor necrosis factor (TNF) therapy 50 and heterogeneity in the genetic background of patients which includes polymorphisms in the MHC (major histocompatibility complex), TRAF1-C5 (encoding tumor necrosis factor receptor-associated factor 1 and complement component 5) 51, STAT4 (encoding signal transducer and activator of transcription 4) 5152 and PTPN22 (encoding protein tyrosine phosphatase, non-receptor type 22) 53 genes. CCP is derived from filaggrin, a protein expressed by keratinocytes in the epidermis, and it is likely that autoantibody reactivity against the CCPs derived from filaggrin represents molecular cross reactivity. Our findings suggest that the development of citrullinated fibrinogen-containing ICs in RA synovial tissue activates the complement cascade and contributes to synovitis in RA.

Conclusion

In summary, the data presented herein suggest that autoimmunity targeting citrullinated fibrinogen and the development of fibrinogen-containing ICs could contribute to synovitis in approximately one-half of anti-CCP+ RA patients. These results expand the possibility for the development of novel diagnostics as well as for the development of specific therapies for this subset of RA patients.

Abbreviations

BSA = bovine serum albumin; CCP = cyclic-citrullinated peptides; FPLC = fast protein liquid chromatography; GPI = glucose-6-phosphate isomerase; HLA = human leucocyte antigen; HRP = horseradish peroxidase; IBD = inflammatory bowel disease; IC = immune complex; JRA = juvenile rheumatoid arthritis; MHC = major histocompatibility complex; PBS = phosphate buffered saline; PBST = phosphate buffered saline with 0.05% Tween-20; PS = psoriasis; PsA = psoriatic arthritis; RA = rheumatoid arthritis; RF = rheumatoid factor; SLE = systemic lupus erythematosus.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

X.Z. and W.H.R. conceived the studies, carried out the experiments, analyzed the data, and wrote the manuscript. N.L.O. and O.S. helped perform the mass spectrometry experiments. F.M.B., A.T.L. and P.K.G. provided human samples and clinical data, and contributed to interpretation of the data. P.P.H. and B.H.T. contributed to data analysis.

Acknowledgements

We thank members of the Robinson laboratory and Elizabeth Chlipala (Premier Laboratory) for their scientific input. This work was funded by a T. Franklin Williams Scholars grant, an Arthritis Foundation Investigator Award, NIH NHLBI contract N01 HV 28183, NIH NIAMS R21 AI069160, and Veterans Affairs Health Care System funding to W.H.R. The mass spectrometry work was supported by the Stanford Digestive Disease Center grant NIH P30 DK56339.

Evolving concepts of rheumatoid arthritis Firestein GS Nature 2003 423 356 361 12748655 Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease Zubler RH Nydegger U Perrin LH Fehr K McCormick J Lambert PH Miescher PA J Clin Invest 1976 57 1308 1319 436784 944196 C1q-bearing immune complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis sera and synovial fluids Antes U Heinz HP Schultz D Brackertz D Loos M Rheumatol Int 1991 10 245 250 2041983 A role for the complement system in rheumatoid arthritis Low JM Moore TL Curr Pharm Des 2005 11 655 670 15720280 Rheumatoid factor avidity in patients with rheumatoid arthritis: identification of pathogenic RFs which correlate with disease parameters and with the gal(0) glycoform of IgG Newkirk MM Fournier MJ Shiroky J J Clin Immunol 1995 15 250 257 8537469 Collagen antibodies and collagen-anticollagen immune complexes in rheumatoid arthritis Steffen C Ludwig H Knapp W Thumb N Eberl R Frank O Freilinger H Z Rheumatol 1975 34 391 399 1108503 Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies Schellekens GA de Jong BA Hoogen van den FH Putte van de LB van Venrooij WJ J Clin Invest 1998 101 273 281 508564 9421490 Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis Kuhn KA Kulik L Tomooka B Braschler KJ Arend WP Robinson WH Holers VM J Clin Invest 2006 116 961 973 1421345 16585962 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis Edwards JC Szczepanski L Szechinski J Filipowicz-Sosnowska A Emery P Close DR Stevens RM Shaw T N Engl J Med 2004 350 2572 2581 15201414 Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA Agrawal S Misra R Aggarwal A Clin Rheumatol 2007 26 201 204 16572283 The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide Schellekens GA Visser H de Jong BA Hoogen van den FH Hazes JM Breedveld FC van Venrooij WJ Arthritis Rheum 2000 43 155 163 10643712 Clinical significance of anti-CCP antibodies in rheumatoid arthritis Mimori T Intern Med 2005 44 1122 1126 16357447 The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin Masson-Bessiere C Sebbag M Girbal-Neuhauser E Nogueira L Vincent C Senshu T Serre G J Immunol 2001 166 4177 4184 11238669 Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids Takizawa Y Suzuki A Sawada T Ohsaka M Inoue T Yamada R Yamamoto K Ann Rheum Dis 2006 65 1013 1020 16449316 From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins Korganow AS Ji H Mangialaio S Duchatelle V Pelanda R Martin T Degott C Kikutani H Rajewsky K Pasquali JL Benoist C Mathis D Immunity 1999 10 451 461 10229188 How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease Matsumoto I Maccioni M Lee DM Maurice M Simmons B Brenner M Mathis D Benoist C Nat Immunol 2002 3 360 365 11896391 A fibrin based model for rheumatoid synovitis Sanchez-Pernaute O Largo R Calvo E Alvarez-Soria MA Egido J Herrero-Beaumont G Ann Rheum Dis 2003 62 1135 1138 1754399 14644849 Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays Cruyssen Vander B Cantaert T Nogueira L Clavel C De Rycke L Dendoven A Sebag M Deforce D Vincent C Elewaut D Serre G De Keyser F Arthritis Res Ther 2006 8 R122 1779401 16859515 Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis Nielen MM Horst van der AR van Schaardenburg D Horst-Bruinsma van der IE Stadt van de RJ Aarden L Dijkmans BA Hamann D Ann Rheum Dis 2005 64 1199 1204 1755615 15640269 Antigen microarray profiling of autoantibodies in rheumatoid arthritis Hueber W Kidd BA Tomooka BH Lee BJ Bruce B Fries JF Sønderstrup G Monach P Drijfhout JW van Venrooij WJ Utz PJ Genovese MC Robinson WH Arthritis Rheum 2005 52 2645 2655 16142722 Gamma globulin complexes in rheumatoid arthritis and certain other conditions Kunkel HG Muller-Eberhard HJ Fudenberg HH Tomasi TB J Clin Invest 1961 40 117 129 290696 13755149 C1q-containing immune complexes purified from sera of juvenile rheumatoid arthritis patients mediate IL-8 production by human synoviocytes: role of C1q receptors Khalkhali-Ellis Z Bulla GA Schlesinger LS Kirschmann DA Moore TL Hendrix MJ J Immunol 1999 163 4612 4620 10510406 Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes Criswell LA Pfeiffer KA Lum RF Gonzales B Novitzke J Kern M Moser KL Begovich AB Carlton VE Li W Lee AT Ortmann W Behrens TW Gregersen PK Am J Hum Genet 2005 76 561 571 1199294 15719322 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arnett FC Edworthy SM Bloch DA McShane DJ Fries JF Cooper NS Healey LA Kaplan SR Liang MH Luthra HS Medsger TA Mitchell DM Neustadt DH Pinals RS Schaller JG Sharp JT Wilder RL Hunder GG Arthritis Rheum 1988 31 315 324 3358796 Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin Vossenaar ER Despres N Lapointe E Heijden van der A Lora M Senshu T van Venrooij WJ Menard HA Arthritis Res Ther 2004 6 R142 150 400433 15059278 IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin Chapuy-Regaud S Nogueira L Clavel C Sebbag M Vincent C Serre G Clin Exp Immunol 2005 139 542 550 1809305 15730401 Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues Senshu T Akiyama K Kan S Asaga H Ishigami A Manabe M J Invest Dermatol 1995 105 163 169 7543546 Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion Agnello V Winchester RJ Kunkel HG Immunology 1970 19 909 919 1455666 4098878 Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis Ferucci ED Majka DS Parrish LA Moroldo MB Ryan M Passo M Thompson SD Deane KD Rewers M Arend WP Glass DN Norris JM Holers VM Arthritis Rheum 2005 52 239 246 15641089 The immunopathology of joint inflammation in rheumatoid arthritis Zvaifler NJ Adv Immunol 1973 16 265 336 4599390 Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Nielen MM van Schaardenburg D Reesink HW Stadt van de RJ Horst-Bruinsma van der IE de Koning MH Habibuw MR Vandenbroucke JP Dijkmans BA Arthritis Rheum 2004 50 380 386 14872479 Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme Matsumoto I Staub A Benoist C Mathis D Science 1999 286 1732 1735 10576739 Immunochemical analyses of components of immune complexes in the sera of patients with autoimmune diseases Ferraccioli G Karsh J Osterland CK J Rheumatol 1983 10 881 888 6663592 Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis Hill JA Al-Bishri J Gladman DD Cairns E Bell DA J Rheumatol 2006 33 2115 2119 16924693 Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis Busso N Hamilton JA Arthritis Rheum 2002 46 2268 2279 12355473 PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease Vossenaar ER Zendman AJ van Venrooij WJ Pruijn GJ Bioessays 2003 25 1106 1118 14579251 Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides Chapuy-Regaud S Sebbag M Baeten D Clavel C Foulquier C De Keyser F Serre G J Immunol 2005 174 5057 5064 15814737 Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides Tilleman K Van Steendam K Cantaert T De Keyser F Elewaut D Deforce D Rheumatology (Oxford) 2008 47 597 604 18326534 Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach Matsuo K Xiang Y Nakamura H Masuko K Yudoh K Noyori K Nishioka K Saito T Kato T Arthritis Res Ther 2006 8 R175 1794520 17125526 Conversion of peanut trypsin-chymotrypsin inhibitor B-III to a chymotrypsin inhibitor by deimination of the P1 arginine residues in two reactive sites Kurokawa T Hara S Takahara H Sugawara K Ikenaka T J Biochem 1987 101 1361 1367 3667552 Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity Lundberg K Nijenhuis S Vossenaar ER Palmblad K van Venrooij WJ Klareskog L Zendman AJ Harris HE Arthritis Res Ther 2005 7 R458 467 1174941 15899032 Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice Hill JA Bell DA Brintnell W Yue D Wehrli B Jevnikar AM Lee DM Hueber W Robinson WH Cairns E J Exp Med 2008 205 967 979 18391064 Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen Wright SD Weitz JI Huang AJ Levin SM Silverstein SC Loike JD Proc Natl Acad Sci USA 1988 85 7734 7738 282267 2971974 An immunohistochemical and immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis Ishikawa H Hirata S Andoh Y Kubo H Nakagawa N Nishibayashi Y Mizuno K Rheumatol Int 1996 16 53 60 8853226 Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding Dejana E Languino LR Polentarutti N Balconi G Ryckewaert JJ Larrieu MJ Donati MB Mantovani A Marguerie G J Clin Invest 1985 75 11 18 423387 3965498 Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4 Smiley ST King JA Hancock WW J Immunol 2001 167 2887 2894 11509636 Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen Clavel C Nogueira L Laurent L Iobagiu C Vincent C Sebbag M Serre G Arthritis Rheum 2008 58 678 688 18311806 Citrullinated proteins in rheumatoid arthritis: crucial but not sufficient! Cantaert T De Rycke L Bongartz T Matteson EL Tak PP Nicholas AP Baeten D Arthritis Rheum 2006 54 3381 3389 17075816 Genetic influences on the end-stage effector phase of arthritis Ji H Gauguier D Ohmura K Gonzalez A Duchatelle V Danoy P Garchon HJ Degott C Lathrop M Benoist C Mathis D J Exp Med 2001 194 321 330 2193468 11489951 Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Moreland LW Schiff MH Baumgartner SW Tindall EA Fleischmann RM Bulpitt KJ Weaver AL Keystone EC Furst DE Mease PJ Ruderman EM Horwitz DA Arkfeld DG Garrison L Burge DJ Blosch CM Lange ML McDonnell ND Weinblatt ME Ann Intern Med 1999 130 478 486 10075615 TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide study Plenge RM Seielstad M Padyukov L Lee AT Remmers EF Ding B Liew A Khalili H Chandrasekaran A Davies LR Li W Tan AK Bonnard C Ong RT Thalamuthu A Pettersson S Liu C Tian C Chen WV Carulli JP Beckman EM Altshuler D Alfredsson L Criswell LA Amos CI Seldin MF Kastner DL Klareskog L Gregersen PK N Engl J Med 2007 357 1199 1209 17804836 STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus Remmers EF Plenge RM Lee AT Graham RR Hom G Behrens TW de Bakker PI Le JM Lee HS Batliwalla F Li W Masters SL Booty MG Carulli JP Padyukov L Alfredsson L Klareskog L Chen WV Amos CI Criswell LA Seldin MF Kastner DL Gregersen PK N Engl J Med 2007 357 977 986 17804842 A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis Begovich AB Carlton VE Honigberg LA Schrodi SJ Chokkalingam AP Alexander HC Ardlie KG Huang Q Smith AM Spoerke JM Conn MT Chang M Chang SY Saiki RK Catanese JJ Leong DU Garcia VE McAllister LB Jeffery DA Lee AT Batliwalla F Remmers E Criswell LA Seldin MF Kastner DL Amos CI Sninsky JJ Gregersen PK Am J Hum Genet 2004 75 330 337 1216068 15208781 Cluster analysis and display of genome-wide expression patterns Eisen MB Spellman PT Brown PO Botstein D Proc Natl Acad Sci USA 1998 95 14863 14868 24541 9843981